Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05081024
Other study ID # STUDY00022247
Secondary ID NCI-2021-08733ST
Status Recruiting
Phase
First received
Last updated
Start date September 3, 2021
Est. completion date September 3, 2024

Study information

Verified date March 2024
Source OHSU Knight Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study measures the levels of circulating tumor DNA (ctDNA) in patients with stage II-III rectal cancer before, during, and after treatment to find out if the presence or absence of ctDNA in patient's blood using the Signatera test can be used to gauge how different treatments may affect rectal cancer. ctDNA is DNA from the rectal cancer that is circulating in the blood. The purpose of this study is to understand if the way rectal tumors respond to standard treatment can be associated with varying levels of ctDNA.


Description:

PRIMARY OBJECTIVE: I. To estimate the percentage of participants that achieve complete clinical response. SECONDARY OBJECTIVES: I. To assess circulating tumor deoxyribonucleic acid (ctDNA) status among participants receiving total neoadjuvant therapy (TNT). II. To assess molecular residual disease (MRD i.e., ctDNA status). III. To assess the rate of transabdominal surgery. IV. To assess the rate pathological complete response after surgery. V. To assess the rate of watch and -wait (W&W) after TNT. VI. To assess disease-free survival (DFS). VII. To assess overall survival (OS). EXPLORATORY OBJECTIVES: I. To characterize ctDNA clearance or non-clearance patterns during TNT. II. To correlate ctDNA levels with a participant's pathological features. III. To preliminary assess the prognostic performance of ctDNA levels in relation to participant's clinical outcome. OUTLINE: Patients undergo collection of blood samples at baseline (before any neoadjuvant therapy), every 2 months while undergoing TNT, and then every 3 months for up to 3 years after completion of TNT. Patients' medical records are also reviewed. Patients may undergo collection of tissue sample if an archival tissue sample is not available.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date September 3, 2024
Est. primary completion date September 3, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participant must provide written informed consent before any study-specific procedures or interventions are performed - Participants aged >= 18 years - Pathologically-confirmed stage II or III primary adenocarcinoma of the rectum: - T3N0M0 - T4bN2M0 Exclusion Criteria: - Has radiologic evidence of distant metastases at the time of screening/enrollment - Has received prior treatment for their rectal adenocarcinoma - Requires or has received blood transfusion within 1 month of study enrollment

Study Design


Intervention

Procedure:
Biopsy
Undergo biopsy
Biospecimen Collection
Undergo collection of blood and/or tissue samples
Other:
Electronic Health Record Review
Medical records are reviewed

Locations

Country Name City State
United States OHSU Knight Cancer Institute Portland Oregon

Sponsors (2)

Lead Sponsor Collaborator
OHSU Knight Cancer Institute Natera, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other ctDNA status positive versus negative results per test results From date of baseline measure of ctDNA (i.e., number of mutant molecules per mL) to date of until the date of first documented progression, up to 3 years
Other Positive ctDNA by clinical characteristics association or recurrence on ctDNA test and standard imaging From date of baseline measure of ctDNA to date of recurrence or death from any cause, assessed up to 3 years following completion of TNT
Other Sensitivity Sensitivity and specificity will be calculated using complete clinical response (yes versus [vs.] no), or tumor recurrence (yes vs. no) as reference standard. From date of baseline measure of ctDNA to date of recurrence or death from any cause, assessed up to 3 years following completion of TNT
Other Specificity Sensitivity and specificity will be calculated using complete clinical response (yes vs. no), or tumor recurrence (yes vs. no) as reference standard. From date of baseline measure of ctDNA to date of recurrence or death from any cause, assessed up to 3 years following completion of TNT
Primary Complete clinical response (cCR) cCR following TNT will be analyzed using the TNT analysis set. Proportions of participants that achieved cCR will be calculated and the exact 95% confidence interval (CI) will be presented. From time of treatment start up to date of completing total neoadjuvant therapy (TNT), up to 3 months.
Secondary Positive circulating tumor deoxyribonucleic acid (ctDNA) The proportion of ctDNA positive participants (at baseline, throughout TNT, and follow-up) and its exact 95% CI will be evaluated using the ctDNA analysis set. Where appropriate, sub-analyses will be conducted using populations that underwent surgery or were monitored using a watch and wait (W&W) strategy. From date of baseline measure of ctDNA (i.e., number of mutant molecules per mL) to date of until the date of first documented progression, up to 3 years.
Secondary Positive ctDNA after completing TNT The proportion of ctDNA positive participants (at baseline, throughout TNT, and follow-up) and its exact 95% CI will be evaluated using the ctDNA analysis set. Where appropriate, sub-analyses will be conducted using populations that underwent surgery or were monitored using a W&W strategy. From date of baseline measure of ctDNA (i.e., number of mutant molecules per mL) to date of until the date of first documented progression, up to 3 years
Secondary Rate of transabdominal surgery Will be evaluated using the TNT analysis set. The corresponding exact 95% CI will also be presented. Up to 3 years following completion of TNT
Secondary Rate of pathological complete response (pCR) Will be evaluated using the TNT analysis set. The corresponding exact 95% CI will also be presented. From start of treatment until completion of surgery, up to 3 years.
Secondary Rate of watch and wait strategy Will be evaluated using the TNT analysis set. The corresponding exact 95% CI will also be presented. Up to 3 years following completion of TNT
Secondary Disease-free survival Will be estimated using the Kaplan-Meier method. Time between the date of surgery (or W&W population, the date of completing TNT) and the date of local or metastatic recurrence or death from any cause, assessed up to 3 years following completion of TNT
Secondary Overall survival Will be estimated using the Kaplan-Meier method. Time between the date of signed consent to the date of death from any cause, assessed up to 3 years following completion of TNT
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04090450 - Optimisation of Radiotherapy in Rectal Cancer (ORREC)
Recruiting NCT06050447 - Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
Terminated NCT02233595 - Evaluation of Rectal Cancer Treatment Response Using PET/MRI
Completed NCT02935309 - Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma Phase 1
Terminated NCT01887509 - Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to Histopathology N/A
Recruiting NCT05746195 - Optimization of Adaptive Text Messages for Cancer Survivors (OATS II) N/A
Active, not recruiting NCT03365882 - S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery Phase 2
Completed NCT02314182 - GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis Phase 3
Completed NCT02393755 - Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer Phase 1/Phase 2
Recruiting NCT04441580 - Assessing the Additional Neoplasia Yield of Computer-aided Colonoscopy in a Screening Setting N/A
Terminated NCT03527784 - Prestoma-Trial for Parastomal Hernia Prevention N/A
Completed NCT00855946 - Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy N/A
Recruiting NCT06328361 - Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer N/A
Recruiting NCT02107105 - Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
Terminated NCT03300544 - Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer Phase 1
Active, not recruiting NCT03436563 - M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Phase 1/Phase 2
Not yet recruiting NCT04814784 - Role of Neoadjuvent Radiotherapy in Locally Advanced Cancer Rectum
Recruiting NCT05482516 - Evaluating Novel Therapies in ctDNA Positive GI Cancers Phase 3
Completed NCT02368886 - Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer Phase 2
Active, not recruiting NCT02688712 - ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer Phase 2